

Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity *in vitro* and *in vivo* in a model of Huntington's disease



Stepanova P¹, Srinivasan V^{2,3}, Lindholm D^{2,3}, and Voutilainen MH¹.

¹Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland. BO Box 56, FIN-00014, University of Helsinki, Finland




²Medicum, Department of Biochemistry and Developmental Biology, Faculty of Medicine, POBox 63, FIN-00014 University of Helsinki, Finland

³Minerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8

[Supplementary information](#)




Supplementary Fig 1. Balance beam test. Rats were lesioned by QA and received CDNF- or PBS-treatment into the same location in two weeks post-lesion. Values are expressed as group mean $\pm$ SEM. No difference between groups in travel time and foot slips number. N number = 15-16.




Supplementary Fig 2. (A) Paw area of forelimbs (fore) and hind limbs (hind). (B) Stride duration of lesion side hind limb (LH) and intact side hind limb (RH). In the relationship between swing and stride phases there was no difference between groups. (C) Stride length. Ratio between intact side (RH) and lesion side (LH). Values are mean $\pm$ SEM. N number per group = 7-8. Left hind limb (LH), right hind limb (RH).

A




B



Supplementary Fig 3. Striatal volume. (A) Quantification of the area of QA-lesioned striatum in CDNF- and PBS-treated groups. (B) The difference of striatal volume between intact and injected sides. There was no statistical difference between groups. Values are expressed as group mean $\pm$ SEM. N number n=19-23 per group.

Supplementary Fig 4. Western blots. Full blots for representative figure 6. Scale repeats the scale of Dual Color marker.



Supplementary figure 5. - Full blots for representative figure 7B and 7C

